# Abridge

*Last Updated: November 2025*

---

## Company Profile

| Field | Details |
|-------|---------|
| **Founded** | 2018 |
| **Headquarters** | Pittsburgh, PA |
| **CEO** | Shiv Rao, MD |
| **Valuation** | $5.3 Billion (June 2025) |
| **Total Raised** | ~$800 Million |
| **Employees** | 300+ |

---

## Funding History

| Round | Date | Amount | Lead Investors |
|-------|------|--------|----------------|
| Series E | June 2025 | $300M | Andreessen Horowitz, Khosla Ventures |
| Series D | Feb 2025 | $250M | Elad Gil, IVP |
| Series C | Feb 2024 | $150M | Lightspeed, Redpoint |
| Earlier | 2018-2023 | ~$100M | Various |

### Key Investors
- a16z, Khosla Ventures, IVP, Lightspeed, Redpoint
- NVentures (NVIDIA's VC arm)
- CVS Health Ventures
- Epic (equity stake + revenue share)
- California Health Care Foundation

---

## Product Overview

### Core Product: Ambient AI Documentation
- Listens to clinical conversations
- Understands medical terminology across 55 specialties
- Supports 28 languages
- Generates structured clinical notes
- Integrates directly into EHR

### Beyond-the-Note Capabilities
- **Revenue Cycle Intelligence** - Billing optimization
- **Clinical Documentation Integrity (CDI)** - Real-time coding suggestions
- **Pre-charting** - Patient context before encounters
- **Prior Authorization** - Abridge + Highmark partnership

---

## Technology Stack

### LLM Approach
- Hybrid: Proprietary models + foundation models
- Custom medical speech recognition
- "Contextual Reasoning Engine" architecture

### NVIDIA Partnership
- NIM inference microservices
- TensorRT-LLM implementation
- GPU-optimized infrastructure

### Data Advantage
- Proprietary training data from consumer app (since 2018)
- Millions of annotated clinical conversations
- Data flywheel from 150+ health systems

---

## EHR Integrations

| EHR | Status |
|-----|--------|
| **Epic** | "First Pal" - Preferred partner, equity relationship |
| **Oracle Cerner** | Full integration |
| **Meditech** | Integration available |
| **athenahealth** | Partnership announced |

### Epic "First Pal" Advantage
- Epic has equity stake in Abridge
- Ongoing revenue share arrangement
- Preferential access to Epic-based health systems (38% of US hospitals)
- Default AI scribe in many Epic-owned systems

---

## Customer Base

### Scale (as of Nov 2025)
- **150+ health systems**
- **Thousands of clinicians**
- **Millions of encounters processed**

### Named Customers
| Health System | Scale |
|--------------|-------|
| Mayo Clinic | Enterprise-wide (2,000+ clinicians) |
| Duke Health | 5,000+ clinicians |
| Johns Hopkins | 6,700+ clinicians |
| Kaiser Permanente | Major deployment |
| UPMC | Large deployment |
| Northwell Health | Partnership |
| Seattle Children's | Deployment |
| UNC Health | Enterprise |
| Emory Healthcare | Deployment |
| Sutter Health | Partnership |

---

## Clinical Outcomes

### Published Results (2025)
- **73%** less after-hours documentation
- **61%** reduced cognitive burden
- **81%** improved workflow satisfaction
- **60-70%** burnout reduction (company claims)
- **90%+** clinician retention rate

### KLAS Recognition
- **Best in KLAS 2025** - Ambient AI Documentation
- Highest customer satisfaction scores
- Consistently outperforming Nuance in new evaluations

---

## Pricing

| Segment | Estimated Price |
|---------|----------------|
| Enterprise | $300-500/provider/month |
| Volume deals | Significant discounts |
| Revenue share | Epic arrangement |

*Pricing competitive with Nuance, not competing on price like Freed*

---

## Strengths

1. **Epic relationship** - Equity, revenue share, "First Pal" status
2. **KLAS leadership** - Best in KLAS 2025
3. **Customer wins** - Mayo, Duke, Johns Hopkins, Kaiser
4. **Technology depth** - Proprietary + foundation model hybrid
5. **Beyond-the-note** - Revenue cycle, CDI, pre-charting expansion
6. **Data flywheel** - 7 years of medical conversation data
7. **NVIDIA partnership** - Infrastructure optimization

---

## Weaknesses

1. **Epic dependence** - Heavy reliance on Epic ecosystem
2. **Valuation pressure** - $5.3B requires massive growth
3. **Competition** - Epic "Art for Clinicians" threat
4. **Non-Epic markets** - Less competitive outside Epic
5. **International** - US-focused, limited global presence

---

## Competitive Positioning

### vs Nuance
- Winning new Epic deals
- Higher KLAS satisfaction
- More innovative, faster moving
- Less expensive in some cases

### vs Epic Native (Art for Clinicians)
- Significant threat announced August 2025
- Abridge differentiating with beyond-the-note
- Deep Epic relationship may provide runway

### vs Nabla
- Abridge stronger in US enterprise
- Nabla stronger in Europe, multi-EHR
- Both expanding beyond documentation

---

## 2025-2026 Outlook

- Expansion of Revenue Cycle Intelligence
- Deeper CDI and coding capabilities
- Response to Epic "Art for Clinicians"
- Potential international expansion
- IPO speculation given valuation

---

## Relevance for Ramsay Health Care

### Pros
- Best-in-class ambient AI
- Beyond-the-note capabilities
- Enterprise-proven at scale

### Cons
- US-focused, limited international
- Epic-centric (Ramsay has diverse EHRs)
- Australian/EU presence unclear
- Language support less than Nabla (28 vs 35+)

---

## Sources

- abridge.com
- Fierce Healthcare funding coverage
- STAT News coverage
- KLAS Research reports
- Health system press releases
- Sacra research report

---

*Analysis by Alex Stinard, MD | Healthcare AI Vendor Analysis Project*
